FDA warned 4 companies, which are claiming that their products containing cannabidiol, can treat or cure cancer.
FDA warned 4 companies, which are claiming that their products containing cannabidiol (CBD), can treat or cure cancer.
Related: FDA warns about contaminated drugs, dietary supplements
FDA warned Greenroads Health, Natural Alchemist, That’s Natural! Marketing and Consulting, and Stanley Brothers Social Enterprises LLC, over unsubstantiated claims on more than 25 different products. The marketers said the products can prevent, reverse or cure cancer, kill cancer cells and tumors; and can treat Alzheimer’s and other serious diseases.
Related: FDA warns about deaths in cancer drug trials
“Substances that contain components of marijuana will be treated like any other products that make unproven claims to shrink cancer tumors. We don’t let companies market products that deliberately prey on sick people with baseless claims that their substance can shrink or cure cancer and we’re not going to look the other way on enforcing these principles when it comes to marijuana-containing products,” said FDA Commissioner Scott Gottlieb, MD, in a statement from FDA. “There are a growing number of effective therapies for many cancers. When people are allowed to illegally market agents that deliver no established benefit, they may steer patients away from products that have proven, anti-tumor effects that could extend lives.”
Unlike drugs approved by the FDA, manufacture of the supplements in question has not been subject to FDA review as part of the drug approval process. In addition, “there has been no FDA evaluation of whether they work, what the proper dosage is, how they could interact with other drugs, or whether they have dangerous side effects or other safety concerns,” FDA said in the statement.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 31st 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 31st 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 31st 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More